文献速递白血病

多组学分析揭示儿童微分化型急性髓系白血病的RUNX1驱动干性与化疗耐药

Multi-omics analysis of pediatric minimally differentiated acute myeloid leukemia reveals RUNX1-driven stemness and chemoresistance.
PubMed 文献 · Leukemia · 2026-04-29

该研究对23例儿童AML-M0进行多组学分析并与1483例白血病样本比较,发现AML-M0呈现整体DNA高甲基化和转录抑制,RUNX1(26%)和ETV6(22%)功能缺失突变频繁,且RUNX1异常与不良预后显著相关;功能实验表明RUNX1敲除导致干细胞样转录特征和化疗敏感性降低。

要点

  • 儿童AML-M0具有整体DNA高甲基化和转录抑制特征。
  • RUNX1功能缺失突变占26%,与不良预后显著相关。
  • RUNX1敲除导致干性特征和对阿糖胞苷及蒽环类敏感性降低。

核心结论

  • 儿童AML-M0以RUNX1驱动干性和化疗耐药为特征,RUNX1异常是重要生物学和临床决定因素。

研究设计与样本

  • 对23例儿童AML-M0进行多组学分析,并与1483例白血病样本比较。
  • 在儿童AML-M0细胞系中使用CRISPR/Cas9介导RUNX1敲除进行功能分析。

主要发现

  • 与非M0 AML相比,AML-M0呈现整体DNA高甲基化和转录抑制,氧化磷酸化和核糖体组装相关基因下调。
  • 基因组分析显示RUNX1功能缺失突变占26%,ETV6占22%,信号通路激活突变占83%(如RAS、FLT3、JAK)。
  • RUNX1改变与不良预后显著相关。
  • RUNX1敲除细胞呈现干细胞样转录特征,氧化磷酸化和核糖体通路基因表达降低。
  • RUNX1破坏与体外对多种药物(包括阿糖胞苷和蒽环类)敏感性降低相关。

临床怎么用

  • RUNX1改变可作为儿童AML-M0的预后标志物。
  • 潜在精准治疗策略包括去甲基化药物、信号通路抑制剂和代谢靶向治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Minimally differentiated acute myeloid leukemia (AML-M0) is a rare and therapeutically challenging subgroup of AML characterized by immature hematopoietic stem cell-like features. To uncover the molecular basis, we conducted a comprehensive multi-omics analysis of 23 pediatric AML-M0 cases and compared them with 1483 leukemia samples. AML-M0 formed a characteristic group that exhibited global DNA hypermethylation and transcriptional suppression, particularly downregulation of genes related to oxidative phosphorylation and ribosome assembly compared to non-M0 AML. Genomic profiling revealed frequent loss-of-function alterations in RUNX1 (26%) and ETV6 (22%), along with activating mutations in signaling pathways (83%), such as RAS, FLT3, and JAK. Notably, RUNX1 alterations were significantly associated with a poor prognosis. Functional analyses using a CRISPR/Cas9-mediated RUNX1 knockout in a pediatric AML-M0 cell line showed stem cell-like transcriptional features and reduced expression of genes related to oxidative phosphorylation and ribosomal pathways. RUNX1 disruption was also associated with reduced in vitro sensitivity to multiple drugs, including cytarabine and anthracyclines. Our study provides the most comprehensive molecular characterization of pediatric AML-M0 to date and identifies RUNX1 alterations as important biological and clinical determinants. These insights highlight the potential strategies for precision therapy, including hypomethylating agents, signaling inhibitors, and metabolic targeting, to improve outcomes.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Kamitori T, Saida S, Mitani K, et al. Multi-omics analysis of pediatric minimally differentiated acute myeloid leukemia reveals RUNX1-driven stemness and chemoresistance. Leukemia. 2026. PMID: 42056531. doi:10.1038/s41375-026-02967-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。